Showing results (221-230 of 235) with videos related to

Sort By:
Pageof 24
Bioorganic & Medicinal Chemistry Letters|September 11, 2004
Nonpeptide alpha V beta 3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backboneDavid B Whitman, Ben C Askew, Le T Duong, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2003
Non-peptide alpha(v)beta(3) antagonists: identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraintJames J Perkins, L T Duong, Carmen Fernandez-Metzler, et al.
The Journal of Steroid Biochemistry and Molecular Biology|May 30, 2008
Agonist-like SERM effects on ERalpha-mediated repression of MMP1 promoter activity predict in vivo effects on bone and uterusAngela Scafonas, Alfred A Reszka, Donald B Kimmel, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2004
Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivativeMichael J Breslin, Mark E Duggan, Wasyl Halczenko, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2002
Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacementsKaren M Brashear, Cecilia A Hunt, Brian T Kucer, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimeticsPaul J Coleman, Ben C Askew, John H Hutchinson, et al.
Bioorganic & Medicinal Chemistry Letters|December 12, 2001
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptideRobert S Meissner, James J Perkins, Le T Duong, et al.
Molecular Endocrinology (Baltimore, Md.)|October 15, 2005
Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylationLorraine Lipfert, John E Fisher, Nan Wei, et al.
Journal of Medicinal Chemistry|October 6, 2000
Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonistM E Duggan, L T Duong, J E Fisher, et al.
The Journal of Biological Chemistry|October 23, 2009
Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glandsAzriel Schmidt, Shun-Ichi Harada, Donald B Kimmel, et al.
Pageof 24